Page data last changed: . Chemistry registry snapshot: . Registry refreshes and identity assessments are separate from scientific content review.
First oral, ghrelin-mimetic diagnostic test for adult growth hormone deficiency.
Also known as: Macrilen · AEZS-130 · ghrelin receptor agonist
Part of the Growth hormone & IGF peptides cluster
Overview
Macimorelin is an orally active ghrelin/growth hormone secretagogue receptor agonist. It was approved by the FDA in 2017 as a diagnostic agent that stimulates growth hormone release to help evaluate adult growth hormone deficiency. This page is educational and is not medical advice.
Source & context
Biological / chemical source: Synthetic orally active peptidomimetic
Primary research or clinical context: FDA-approved oral diagnostic agent for adult growth hormone deficiency (prescription)
A diagnostic, not a treatment
Macimorelin is used to provoke a measurable growth hormone response. Because it is taken by mouth, it offers a simpler alternative to older stimulation tests such as the insulin tolerance test for assessing adult GH deficiency.
Ghrelin-mimetic action
By activating the growth hormone secretagogue receptor, macimorelin mimics ghrelin's ability to trigger pituitary GH release. This links it conceptually to research GH secretagogues such as ipamorelin and the GHRP family.
Structure & chemistry
Molecular identity & reference confidence
Source-supported reference
Reference values are taken from the cited molecular record or curated profile. A database match is not independent laboratory verification; modifications, counter-ions, and formulations can change the measured mass.
- Molecular form
- Macimorelin (source record; form not independently established)
- Species
- Not established by this molecular identity audit
- Termini (N / C)
- Not specified / Not specified
Average reference mass
Reference policy updated: 2026-10-05
- IUPHAR/BPS source snapshot · 2026-10-01
- PubChem molecular record · 2026-10-01
- Molecular formula
- C26H30N6O3
- Average reference mass
- ≈ 474.6
- Status
- Approved medicine in at least one jurisdiction (IUPHAR record)
- PubChem CID: 9804938
- IUPHAR ligand: 9745
- ChEMBL: CHEMBL278623
- CAS RN: 381231-18-1
- UNII: 8680B21W73
Chemistry values: PubChem, IUPHAR/BPS Guide to Pharmacology · fetched 2026-10-01.
Clinical development snapshot
ClinicalTrials.gov lists 6 registered studies with “Macimorelin” as an intervention (snapshot 2026-09-06). A registry footprint is not evidence of efficacy or approval.
| NCT | Title | Phase | Status | Updated |
|---|---|---|---|---|
| NCT04786873 | A Research Study of How Well Macimorelin Works to Find Out if Children Have a Lack of Growth Hormone and How S | Phase 3 | completed | 2024-08-12 |
| NCT01614990 | Pilot Clinical Trial of Repeated Doses of Macimorelin to Assess Safety and Efficacy in Patients With Cancer Ca | Phase 2 | completed | 2024-03-20 |
| NCT03844217 | Copeptin After an Oral Stimulation With Macimorelin in Healthy Volunteers | Not applicable | completed | 2019-08-08 |
| NCT00448747 | Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test. | Phase 3 | completed | 2019-07-23 |
| NCT02558829 | Validation of Macimorelin as a Test for Adult Growth Hormone Deficiency | Phase 3 | completed | 2018-04-10 |
| NCT00377377 | Oral Ghrelin Agonist in Healthy Subjects | Phase 1 | completed | 2007-05-03 |
Macimorelin — reconstitution calculator
Enter how much peptide is in the vial and how much diluent (e.g. bacteriostatic water) is added. The tool returns the resulting solution concentration — and, for any amount you type, the volume it corresponds to. This is educational arithmetic, not a dosing recommendation.
Reference form: Macimorelin (source record; form not independently established)Average reference mass: 474.6 Da
Enter an amount to see the volume it corresponds to.
Educational concentration mathematics only. This tool does not recommend a dose, amount, or protocol, and nothing here is medical advice. Many peptides are not authorized by Health Canada for human use — see our reconstitution and bacteriostatic-water guides for context.
FAQ about Macimorelin
What is Macimorelin?+
Macimorelin is an orally active ghrelin/growth hormone secretagogue receptor agonist. It was approved by the FDA in 2017 as a diagnostic agent that stimulates growth hormone release to help evaluate adult growth hormone deficiency. This page is educational and is not medical advice.
What Canadian product status is recorded for Macimorelin?+
Canadian product status for Macimorelin has not been verified in this profile. No verified record here does not mean no authorization exists. Status depends on the product, formulation and use; consult Health Canada's product records.
What is the typical length of Macimorelin?+
Macimorelin is not a classic amino-acid chain peptide in the same sense; see the profile for classification details.
Related peptides
References & further reading
- 1.Henry (2022). Macimorelin Acetate for the Diagnosis of Childhood-onset Growth Hormone Deficiency. touchREV Endocrinol
- 2.Garcia et al. (2018). Macimorelin as a Diagnostic Test for Adult GH Deficiency. J Clin Endocrinol Metab
- 3.Garcia et al. (2013). Macimorelin (AEZS-130)-stimulated growth hormone (GH) test: validation of a novel oral stimulation test for the diagnosis of adult GH deficiency. J Clin Endocrinol Metab
- 4.Yadav et al. (2026). Real-world diagnostic performance of the macimorelin stimulation test in the diagnosis of adult growth hormone deficiency. Pituitary
- 5.Herodes et al. (2023). Pilot clinical trial of macimorelin to assess safety and efficacy in patients with cancer cachexia. J Cachexia Sarcopenia Muscle
- 6.Lissy et al. (2021). Thorough QT/QTc Study Evaluating the Effect of Macimorelin on Cardiac Safety Parameters in Healthy Participants. Clin Pharmacol Drug Dev
- 7.Wang et al. (2025). Molecular recognition of two approved drugs Macimorelin and Anamorelin by the growth hormone secretagogue receptor. Acta Pharmacol Sin
- 8.Garcia et al. (2021). Sensitivity and specificity of the macimorelin test for diagnosis of AGHD. Endocr Connect
- 9.PubChem — compound summary for Macimorelin (CID 9804938)
- 10.Wikipedia — Macimorelin